Pharnext’s Pivotal Phase 3 Trial PLEO-CMT to Be Featured at the 22nd Edition of the Francophone Peripheral Nerve Society Co...
January 18 2018 - 10:45AM
Business Wire
Regulatory News:
Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA),
a biopharmaceutical company pioneering a new approach to the
development of innovative drugs based on the combination and
repositioning of known drugs, today announced the Company will
present an update from its ongoing pivotal Phase 3 clinical trial
PLEO-CMT evaluating PXT3003 for the treatment of
Charcot-Marie-Tooth type 1A disease (CMT1A), in an oral session
during the 22nd edition of the Francophone Peripheral Nerve Society
conference. The gathering will take place on January 26-27, 2018 in
Paris (France).
Details of the presentation are as follows:
Date
Time
Session
FridayJanuary26,2018
From 3:03to 3:15pmCET
Selected Oral Communications
Session
- Title: Status of the Pivotal Phase III Study (PLEO-CMT)
Assessing the Efficacy andSafety of PXT3003 in the Treatment of
Adult Patients with Charcot-Marie-Toothtype 1A
- Speaker : Prof. Shahram Attarian (Marseille)
For more information about the event please visit :
www.journeessfnp.fr/programme
About PharnextPharnext is an advanced clinical-stage
biopharmaceutical company founded by renowned scientists and
entrepreneurs including Professor Daniel Cohen, a pioneer in modern
genomics. Pharnext has two lead products in clinical development.
PXT3003 is currently in an international Phase 3 trial for the
treatment of Charcot-Marie-Tooth disease type 1A and benefits from
orphan drug status in Europe and the United States. PXT864 has
generated positive Phase 2 results in Alzheimer’s disease. Pharnext
is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The
Company identifies and develops synergic combinations of
repositioned drugs at new optimal lower doses. These PLEODRUG™
offer several key advantages: efficacy, safety and intellectual
property, including several product or composition of matter
patents already granted. The Company is supported by a world-class
scientific team.
Pharnext is listed on Euronext Growth Stock Exchange in Paris
(ISIN code: FR0011191287).
For more information, visit www.pharnext.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180118005972/en/
PharnextRené Goedkoop,+33 (0)1 41 09 22 30Chief Medical
Officermedical@pharnext.comorInvestor Relations (Europe)MC
Services AGAnne Hennecke, +49 211 529252
22anne.hennecke@mc-services.euorInvestor Relations
(U.S.)Stern Investor Relations, Inc.Matthew Shinseki, +1 212
362 1200matthew@sternir.comorFinancial Communication
(France)ActifinStéphane Ruiz, +33 (0)1 56 88 11
15sruiz@actifin.frorMedia Relations (Europe)ALIZE RPCaroline
CarmagnolAurore Gangloff+33 (0)1 44 54 36
64pharnext@alizerp.comorMedia Relations
(U.S.)RooneyPartnersMarion Janic, +1 212 223
4017mjanic@rooneyco.com
Pharnext (EU:ALPHA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pharnext (EU:ALPHA)
Historical Stock Chart
From Apr 2023 to Apr 2024